The committee responsible for U.S. vaccination schedules gave a preferential recommendation to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck’s established product Zostavax.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Tecentriq has lost market share to Merck & Co.’s rival Keytruda since a study showed Roche’s immunotherapy drug failed to improve overall survival in bladder cancer.
House Committee on Oversight and Government Reform Democrats are launching an investigation into why prices for MS treatments have nearly quadrupled since 2004.
Radicava (edaravone), an intravenous therapy indicated for all adult patients diagnosed with Lou Gehrig’s disease, has been launched in the U.S. by Mitsubishi Tanabe.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.
The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.
First Year After Launch: New molecular entities launched in the U.S. during 2015 that generated 2016 sales of at least $200 million
A listing of the the new molecular entities launched in the United States during 2015 that generated 2016 sales of at least $200 million